| Literature DB >> 18065501 |
Kelly A Berg1, John Dunlop, Teresa Sanchez, Michelle Silva, William P Clarke.
Abstract
The post-transcriptional process of mRNA editing changes up to three amino acids in the second intracellular domain (i2) of the serotonin(2C) (5-HT(2C)) receptor and alters some signaling characteristics of the receptor. Here, we report that the substitution of valine for isoleucine (I156V; 5-HT(2C-VNI)), which occurs naturally as a result of mRNA editing, alters both ligand-dependent and -independent signaling. Agonist functional selectivity at the 5-HT(2C-VNI) receptor differed from the nonedited 5-HT(2C-INI) receptor. Ligands with selectivity for phospholipase C (PLC) signaling in 5-HT(2C-INI) cells retained this selectivity in 5-HT(2C-VNI)-expressing cells. However, ligands with selectivity for phospholipase A2 (PLA2) signaling in 5-HT(2C-INI) cells lost the capacity for preferential PLA2 activation in 5-HT(2C-VNI) cells. Maximal PLC responses elicited by 5-HT (full agonist) and lysergic acid diethylamide and 2,5-dimethoxy-4-iodophenylisopropylamine (partial agonists) at edited receptors (5-HT(2C-VNI), 5-HT(2C-VSV), and 5-HT(2C-VGV)) were not different from 5-HT(2C-INI) receptors, suggesting that the capacity of the agonist-occupied receptor to couple to G(q/11) proteins was not different. Ligand-independent (i.e., constitutive) receptor activity toward PLC for the 5-HT(2C-VNI) receptor was markedly reduced to a level similar to that for the fully edited 5-HT(2C-VSV) isoform. However, there was no difference in the thermal stability of the edited receptors, suggesting that mRNA editing does not alter the capacity of receptors to adopt active conformations. These results indicate that a conservative change in one amino acid (I156V) located in i2 of the 5-HT(2C) receptor produces profound changes in receptor function that differ depending upon whether the receptor is unoccupied or occupied by agonist.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18065501 DOI: 10.1124/jpet.107.131524
Source DB: PubMed Journal: J Pharmacol Exp Ther ISSN: 0022-3565 Impact factor: 4.030